

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

June 3, 2024

Paul Song Chief Executive Officer NKGen Biotech, Inc. 3001 Daimler St. Santa Ana, CA 92705

Re: NKGen Biotech, Inc.
Amendment No. 3 to Registration Statement on Form S-1
Filed May 13, 2024
File No. 333-275094

Dear Paul Song:

We have reviewed your amended registration statement and have the following comments.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our December 20, 2023 letter.

Amendment No. 3 to Registration Statement on Form S-1

## General

- 1. Please provide your analysis showing how you determined that there was a completed private placement for the following:
  - 750,000 shares of NKGen common stock issuable to AJB which may be issued in up to three additional tranches at AJB's discretion under the Second AJB SPA; and
  - 1,250,000 shares of NKGen common stock issuable to Alpha which may be issued in up to three additional tranches at Alpha's discretion under the Alpha SPA In your analysis, please consider the Commission's guidance set forth in Questions 134.01

and 139.06 of the Securities Act Sections Compliance and Disclosure Interpretations.

Paul Song NKGen Biotech, Inc. June 3, 2024 Page 2

## Cover Page

2. We note you appear to have issued common stock as consideration shares under certain unsecured notes agreements. Please revise your disclosure here and on page 57 to clarify that these selling securityholders may experience a positive rate of return based on the current trading price and disclose the potential profit the selling securityholders will earn based on the current trading price.

<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>
<u>Overview, page 67</u>

- 3. Please expand your discussion here to reflect the fact that this offering involves the potential sale of a substantial portion of shares for resale and discuss how such sales could impact the market price of the company's common stock.
- 4. We refer to comment 1 of our letter dated December 8, 2023. Please restore the prior disclosure responsive to this comment that explained in plain English the mechanics of your Forward Purchase Agreements and any related agreements. Your revisions should also update this disclosure to discuss the subsequent changes to the terms of these agreements, such as your April 14, 2024 amendment to the Sandia Forward Purchase Agreement capping the Reset Price at \$1.2743 and its effect.

Please contact Tyler Howes at 202-551-3370 or Jason Drory at 202-551-8342 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Michael J. Blankenship, Esq.